MSD Leading in Oral COVID-19 Drug Race in Japan, Trailed by Pfizer; Shionogi Top Domestic Player

The development of oral antiviral drugs for COVID-19 is making headway in Japan, with MSD leading the pack with its late-stage compound molnupiravir. Pfizer follows with PII/III-ready PF-07321332, while Shionogi pursues S-217622 in PI, the most advanced program among products...read more